Gene · 2767
Papers2,923
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 2,923
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Cancer Vaccine Targeting Mutated GNAQ-Expressing Uveal Melanoma. | Cancers (Basel) | 2026 | 41681951 | PubTator, text mining | PubMed |
| Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial. | Acta Oncol | 2026 | 41664938 | PubTator, text mining | PubMed |
| Chromosome 3p deletion leads to extensive genomic alterations in diverse cancers and confers synthetic lethality in uveal melanoma. | bioRxiv | 2026 | 41648238 | PubTator, text mining | PubMed |
| Calcineurin-NFAT-DSCR1.4 signaling as druggable axis in Gαq-R183Q-driven capillary malformations. | Angiogenesis | 2026 | 41636844 | PubTator, text mining | PubMed |
| Clinical Molecular Pathology and Treatment Developments in Advanced Uveal Melanoma: State of the Art. | Oncol Res | 2026 | 41613812 | PubTator, text mining | PubMed |
| Endocrine Disorders of Calcium Signaling in Children: Neuroendocrine Crosstalk and Clinical Implications. | Cells | 2026 | 41597215 | PubTator, text mining | PubMed |
| Circulating Tumor Cells in Uveal Melanoma: Multi-Marker Detection and Association With Disease State. | Invest Ophthalmol Vis Sci | 2026 | 41590605 | PubTator, text mining | PubMed |
| Gene discovery in extensive dermal melanocytosis reveals multiple mosaic causes. | Br J Dermatol | 2026 | 41308076 | PubTator, text mining | PubMed |
| Expanding the Molecular Characterization of Adenoid Ameloblastoma by Assessing a Panel of Oncogenes and Tumor Suppressor Genes. | Mod Pathol | 2026 | 41109353 | PubTator, text mining | PubMed |
| Visualizing Genetics: An Investigation of Dermoscopy as a Tool for Genetic Variant Prediction in Capillary Malformations. | Pediatr Dermatol | 2026 | 41063333 | PubTator, text mining | PubMed |
| Artificial intelligence-assisted assessment of metabolic response to tebentafusp in metastatic uveal melanoma: a long axial field-of-view [18F]FDG PET/CT study. | Eur J Nucl Med Mol Imaging | 2026 | 40913640 | PubTator, text mining | PubMed |
| Immunohistochemical and molecular profiling of uveal melanoma: clinicopathological correlations from an Italian cohort. | Pathologica | 2025 | 41954344 | PubTator, text mining | PubMed |
| Current Therapies and Potential Strategies for Uveal Melanoma. | Drugs Drug Candidates | 2025 | 41737289 | PubTator, text mining | PubMed |
| Liquid Biopsy and Automated Next-Generation Sequencing: Achieving Results in 27 Hours Within a Community Setting. | Diagnostics (Basel) | 2025 | 41515531 | PubTator, text mining | PubMed |
| Unraveling Resistance Mechanisms to Gαq Pathway Inhibition in Uveal Melanoma: Insights from Signaling-Activation Library Screening. | Cancers (Basel) | 2025 | 41514587 | PubTator, text mining | PubMed |
| Uveal Melanocytoma without GNAQ/GNA11 Mutations. | Ocul Oncol Pathol | 2025 | 41403972 | PubTator, text mining | PubMed |
| Longitudinal ctDNA monitoring in patients with metastatic uveal melanoma undergoing isolated hepatic perfusion in combination with ipilimumab and nivolumab. | Immunooncol Technol | 2025 | 41362699 | PubTator, text mining | PubMed |
| Sorafenib as first-line therapy for metastatic uveal melanoma: A multicenter, placebo-controlled randomized discontinuation study (STREAM). | iScience | 2025 | 41362626 | PubTator, text mining | PubMed |
A novel homozygous c.301T > C, p.Y101H variant in the GNA11 gene is implicated in familial hypocalciuric hypercalcemia type 2 in a proband with the heterozygous variant present in mother and father - A case report. | Scand J Clin Lab Invest | 2025 | 41240382 | PubTator, text mining | PubMed |
| Molecular investigation of primary aldosteronism: exploring genetic heterogeneity in understudied populations. | Arch Endocrinol Metab | 2025 | 41196931 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2767/papers?page=4